<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04627571</url>
  </required_header>
  <id_info>
    <org_study_id>20-000833</org_study_id>
    <nct_id>NCT04627571</nct_id>
  </id_info>
  <brief_title>Corneal Nerves After Treatment With Cenegermin</brief_title>
  <official_title>Structural and Functional Changes of Corneal Innervation After Treatment With Cenegermin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neurotrophic keratopathy (NK) is a condition in which patients have fewer or complete absence&#xD;
      of nerves in the cornea, characterized by the reduced or absent corneal sensation. The lack&#xD;
      of nerves in the cornea also result in damages of the cornea and in severe situation the loss&#xD;
      of the eye.&#xD;
&#xD;
      Cenegermin (trade name Oxervate) is a nerve growth factor eye drops designed to treat NK, and&#xD;
      currently, it is the only FDA-approved medication for this purpose.&#xD;
&#xD;
      Even though cenegermin is effective in the majority of patients, there is a lack of&#xD;
      understanding of how cenegermin works in the eye.&#xD;
&#xD;
      In this study, investigators aim to determine the structural and functional effects of&#xD;
      cenegermin on the cornea, using non-invasive technologies including in vivo confocal&#xD;
      microscopy on study participants with NK over the course of a year.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cenegermin (OxervateTM) is a recombinant human form of nerve growth factor developed by Dompé&#xD;
      Farmaceutici S.p.A. for patients who are diagnosed with corneal epithelial defects due to&#xD;
      moderate to severe stages of NK.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in corneal nerve fiber density (CNFD)</measure>
    <time_frame>1 year</time_frame>
    <description>To determine the changes in corneal nerve fiber density (CNFD), assessed by in vivo confocal microscopy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of changes in CNFD</measure>
    <time_frame>1 year</time_frame>
    <description>To determine the duration of the changes in corneal nerve fiber density (CNFD), assessed by in vivo confocal microscopy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Presence/absence of Changes in Dry Eye Symptom</measure>
    <time_frame>1 year</time_frame>
    <description>To determine changes in dry eye symptom scores assessed by the Ocular Surface Disease Index in patients initiated on cenegermin for recalcitrant neurotrophic keratopathy. A score ranges from 0 to 100 with scores 0 to 12 representing normal, 13 to 22 representing mild dry eye disease, 23 to 32 representing moderate dry eye disease, and greater than 33 representing severe dry eye disease.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Tear Production</measure>
    <time_frame>1 year</time_frame>
    <description>To determine the changes in tear production in patients initiated on cenegermin for recalcitrant neurotrophic keratopathy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Tear Characteristics</measure>
    <time_frame>1 year</time_frame>
    <description>To determine the changes in tear film osmolarity in patients initiated on cenegermin for recalcitrant neurotrophic keratopathy.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Neurotrophic Keratitis</condition>
  <arm_group>
    <arm_group_label>Patient Population</arm_group_label>
    <description>Patients diagnosed with neurotrophic keratopathy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cenegermin Ophthalmic Solution [Oxervate]</intervention_name>
    <description>An 8-week course of topical cenegermin eye drops given 6 times daily would be started in the affected eye, in conjunction with the pre-existing medical treatment for neurotrophic keratopathy. Patients will be followed-up at 4 weeks, 6 weeks, 8 weeks, 3 months, 6 months, 9 months and 12 months (±2 weeks at each time point) after treatment. At each visit, patients will be assessed to determine the corneal epithelial defect and corneal sensation.</description>
    <arm_group_label>Patient Population</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are 18 years of age or older, who have a persistent corneal epithelial defect&#xD;
        due to neurotrophic keratopathy that is refractory to conventional non-surgical treatments&#xD;
        for 2 weeks or more, and who fulfill the inclusion and exclusion criteria detailed above.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Patients ≥18 years of age; AND&#xD;
&#xD;
          2. Persistent corneal epithelial defect that is refractory to conventional non-surgical&#xD;
             treatments for ≥2 weeks; AND&#xD;
&#xD;
          3. Evidence of decreased corneal sensitivity, defined as ≤45mm on Cochet-Bonnet&#xD;
             esthesiometer, within the area of the persistent corneal epithelial defect; AND&#xD;
&#xD;
          4. Evidence of decreased corneal sensitivity, defined as above, in ≥1 corneal quadrant&#xD;
             outside the persistent corneal epithelial defect.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Patients with severe neurotrophic keratopathy characterized by corneal stromal&#xD;
             ulceration involving over 75% of the total central corneal thickness and impending&#xD;
             perforation.&#xD;
&#xD;
          2. Patients who had been using or who are going to use autologous serum eyedrops,&#xD;
             plasma-rich plasma eyedrops, or umbilical cord eyedrops for the treatment of&#xD;
             neurotrophic keratopathy.&#xD;
&#xD;
          3. Ocular surgery (including laser or refractive surgical procedures) within three months&#xD;
             before study enrollment.&#xD;
&#xD;
          4. Presence of concurrent bacterial or fungal infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Simon Fung, MD</last_name>
    <phone>310-794-9581</phone>
    <email>simonfung@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julliane Bacerdo, B.S.</last_name>
    <phone>310-794-5538</phone>
    <email>jbacerdo@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julliane Bacerdo, B.S</last_name>
      <phone>310-794-5538</phone>
      <email>jbacerdo@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Simon Fung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony Aldave, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saba Al-Hashimi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Deng, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://link.springer.com/article/10.1007/s40135-020-00228-y</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Sacchetti M, Lambiase A. Diagnosis and management of neurotrophic keratitis. Clin Ophthalmol. 2014 Mar 19;8:571-9. doi: 10.2147/OPTH.S45921. eCollection 2014. Review.</citation>
    <PMID>24672223</PMID>
  </reference>
  <reference>
    <citation>Bonini S, Lambiase A, Rama P, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology. 2000 Jul;107(7):1347-51; discussion 1351-2.</citation>
    <PMID>10889110</PMID>
  </reference>
  <reference>
    <citation>Lambiase A, Sacchetti M, Bonini S. Nerve growth factor therapy for corneal disease. Curr Opin Ophthalmol. 2012 Jul;23(4):296-302. doi: 10.1097/ICU.0b013e3283543b61. Review.</citation>
    <PMID>22543481</PMID>
  </reference>
  <reference>
    <citation>Bonini S, Lambiase A, Rama P, Filatori I, Allegretti M, Chao W, Mantelli F; REPARO Study Group. Phase I Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis. Ophthalmology. 2018 Sep;125(9):1468-1471. doi: 10.1016/j.ophtha.2018.03.004. Epub 2018 Apr 10.</citation>
    <PMID>29653861</PMID>
  </reference>
  <reference>
    <citation>Ting DSJ. Re: Bonini et al.: Phase 2 randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis (Ophthalmology. 2018;125:1332-1343). Ophthalmology. 2019 Feb;126(2):e14-e15. doi: 10.1016/j.ophtha.2018.09.017.</citation>
    <PMID>30683186</PMID>
  </reference>
  <reference>
    <citation>Pflugfelder SC, Massaro-Giordano M, Perez VL, Hamrah P, Deng SX, Espandar L, Foster CS, Affeldt J, Seedor JA, Afshari NA, Chao W, Allegretti M, Mantelli F, Dana R. Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial. Ophthalmology. 2020 Jan;127(1):14-26. doi: 10.1016/j.ophtha.2019.08.020. Epub 2019 Aug 26.</citation>
    <PMID>31585826</PMID>
  </reference>
  <reference>
    <citation>Mastropasqua L, Lanzini M, Dua HS, D' Uffizi A, Di Nicola M, Calienno R, Bondì J, Said DG, Nubile M. In Vivo Evaluation of Corneal Nerves and Epithelial Healing After Treatment With Recombinant Nerve Growth Factor for Neurotrophic Keratopathy. Am J Ophthalmol. 2020 Sep;217:278-286. doi: 10.1016/j.ajo.2020.04.036. Epub 2020 May 6.</citation>
    <PMID>32387431</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 8, 2020</study_first_submitted>
  <study_first_submitted_qc>November 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>October 2, 2021</last_update_submitted>
  <last_update_submitted_qc>October 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Simon Fung</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>cenegermin</keyword>
  <keyword>neurotrophic keratopathy</keyword>
  <keyword>corneal nerve</keyword>
  <keyword>corneal sensation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

